Cancer Biomarkers Market Revenue to Attain USD 39.41 Bn by 2033

21 Apr 2025

Share :

Table of Content

1. Cancer Biomarkers Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Report Highlights 4. Market Trends 5. Regional Insights 6. Cancer Biomarkers Market Coverage 7. Market News 8. Cancer Biomarkers Market Key Players 9. Market Segmentation

Cancer Biomarkers Market Revenue and Trends 2025 to 2033

The global cancer biomarkers market revenue was valued at USD 15.58 billion in 2025 and is expected to attain around USD 39.41 billion by 2033, growing at a CAGR of 11.19% during forecast period. The cancer biomarkers market develops due to growing cancer rates, improved personalized medicine approaches, and rising R&D activities.

Market Overview

Cancer biomarkers, such as proteins, genes, and other substances in bloodstreams and tissue samples that function as warning signs of cancer development and disease advancement. The discovery and examination of biomarkers hold essential value during cancer diagnostic processes, treatment progress observations, and customized therapy development. Cancer biomarkers continue to expand their use in applications such as diagnostic testing, drug research, patient prognosis assessments, and custom treatment methods.

Rising cancer occurrences of prostate, lung, and breast cancers drive market growth because they intensify the necessity to detect diseases at early stages accurately. The precision of cancer biomarkers increased because of proteomics and genomics advancements, which improved diagnostic accuracy while improving the monitoring of patient treatment. The public and private sector funding of cancer research has driven faster advancements in cancer diagnostic techniques.

Report Highlights

• type, the breast cancer segment will hold the largest market share in 2024. Breast cancer expands because the disease affects many people while genomic and proteomic technologies advance research receives more funding and the medical sector focuses more on personalized care. The lung cancer segment is anticipated to experience the highest CAGR throughout the forecast period. The elderly population mainly develops lung cancer, which appears as their primary disease.
• By biomolecule, the genetic biomarkers segment registered the dominant market share in 2024. Genomic technologies have advanced through development to create precise genetic mutation identification systems that link them to cancer risk and development. The epigenetics segment is expected to grow rapidly over the forecast period. The rising scientific initiatives focused on building new epigenetic biomarkers.
• By technology, in 2024, the imaging technologies segment led the market share because of its characteristics, precision, and wide-ranging use in biomarker discovery and diagnosis. The OMICS segment is anticipated to experience the highest CAGR throughout the forecast period. OMICS technologies are crucial for developing cancer biomarkers as they provide a comprehensive analysis of tumors using genomic, proteomic, and metabolomic data measurements.
• By application, the diagnostics segment captured the biggest revenue share in 2024. The segment experienced increased growth because of emerging efficient oncology test-based cancer biomarkers and rising government initiatives. The personalized medicine segment will expand significantly during the forecast period. The market advances in personalized medicine because research into genomic and proteomic technologies allows scientists to find biomarkers that predict patient treatment responses, thus improving treatment accuracy and results.

Market Trends

Biomarkers in Personalized Cancer Care

Biomarkers have a key role in the personalization of cancer therapies whereby physicians can personalize treatment by the genetic profile of the patient and tumor type. Furthermore, the use of biomarkers maximizes the proficiency and accuracy of cancer treatment, ultimately maximizing the benefit of the cancer treatment to the patient.

Rising Cancer Prevalence

The rising incidence rates of cancer throughout the world are a key driver for the cancer biomarkers market. Increasing incidence rates of cancer types due to aging populations, lifestyle, and environmental factors are all contributors.

Increasing R&D Activities

The increasing burden of healthcare requires improved diagnostic and therapeutic methods, including biomarker-based methods for early diagnosis and personalized treatment, and is driving innovation and research and development initiatives in oncology. Organizations engaged in research and development activities have increased their focus and investment around cancer biomarkers in response to the increasing burden towards improved diagnostic and therapeutic options.

Regional Insights

North America dominated the cancer biomarkers market in 2024. The implementation of several diagnostic procedures has improved treatment outcomes for patients by increasing the precision of the diagnosis and enabling tailored treatment. Investments enable researchers to further develop innovative cancer diagnosis and treatment biomarker technologies. The cancer biomarkers market expands and dominates North America because of its supportive regulatory aspect, technological advancements, and strong funding support for research.

• In July 2024, the American Lung Association introduced Biomarker Education Awareness and Testing (BEAT) Lung Cancer as a new initiative to enhance biomarker understanding in communities facing lung cancer inequality. 

Asia Pacific is anticipated to be the fastest-growing region in the cancer biomarkers market. With increasing cancer case rates in countries such as China, Japan, and India, governments are enhancing funding for research and development, encouraging market growth.  Further improvements have been made to the healthcare infrastructure within the region, expanding the ability to adopt these biomarker tests. Local governments are putting policies in place to tackle the impact of cancer, especially among women, which should help boost public health overall.

Cancer Biomarkers Market Coverage

Market News

• In April 2025, ICR Scientists launched a next-generation artificial intelligence platform that lets researchers analyze large complex clinical trial datasets to speed up the development of new cancer biomarkers. 
• In September 2024, QIAGEN N.V. released the QIAcuityDx Digital PCR System as an instrument that delivers accurate absolute quantification of DNA and RNA targets for minimally-invasive liquid biopsy applications. The system supports oncological surveillance through its progressive cancer assessments while enhancing traditional cancer detection practices.
• In August 2024, TruSight Oncology Comprehensive obtained FDA clearance from Illumina, Inc. as an in vitro diagnostic test for analyzing more than five hundred genes in solid tumor specimens.

Cancer Biomarkers Market Key Players

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Abbott Laboratories
• Exact Sciences
• Meso Scale Diagnostics LLC
• Seegene Technologies Inc.
• Siemens Healthineers

Market Segmentation

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Profiling Technology

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests

By End User

• Hospitals
• Academic and Cancer Research Institutes
• Ambulatory Surgical Centres
• Diagnostic Laboratories

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/1637 

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344